CC Tea inks research pact with Assam institute
Source: Chronicle News Service
Imphal, August 31 2021:
Manipur-based SuiGeneris Agronomy Private Limited (CC Tea manufacturer) on Tuesday signed a three year deal for anti-cancer research collaboration with Assam's Dr B Barooah Cancer Institute to assess the efficacy of CC Tea extract on molecular pathways in lymphocytes and other blood cells of cancer patients of North-East India.
In a release, SuiGeneris public relations head Sam Khumanthem said it is a three phased research undertaking and would begin with CC Tea extract tested on blood cells taken from cancer patients and conclude with the product being tested on patients directly.
The company recently concluded a 6-month anti-viral and immunomodulatory research with Indian Institute of Technology, Guwahati too and found that CC Tea showed high anti-viral activity to the Japanese Encephalitis Virus (JEV) and Newcastle Disease Virus (NDV).
It also suggests positive innate immune activation in gene analysis, added the release.
Chairman and CEO of SuiGeneris Ragesh Keisham also mentioned that over the years, they have received encouraging feedbacks from users on various health related benefits after prolonged use of CC Tea.
"The research collaboration with Dr B Barooah Cancer Institute is a proof of our commitment for a relentless fight against cancer," he said.
The Cancer Institute in volved in quality medical research and healthcare.
It was formally taken over by Department of Atomic Energy, Government of India on November 27, 2017 as a unit of Tata Memorial Centre, Mumbai.